(Q33437445)

English

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi (English)

1 reference

Europe PubMed Central

26 July 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Simone Ferrero

5

0 references

Annalisa Chiappella

object named as

Annalisa Chiappella

2

0 references

object named as

Marco Ladetto

21

0 references

object named as

Michele Spina

8

0 references

object named as

Umberto Vitolo

26

0 references

Gianluca Gaidano

23

object named as

Gianluca Gaidano

2 references

Europe PubMed Central

26 July 2017

ORCID Public Data File 2021

Stefano A Pileri

20

object named as

Stefano A Pileri

1 reference

Europe PubMed Central

26 July 2017

Graziella Pinotti

13

object named as

Graziella Pinotti

1 reference

Europe PubMed Central

26 July 2017

Giovannino Ciccone

22

object named as

Giovannino Ciccone

1 reference

Europe PubMed Central

26 July 2017

19

object named as

Flavia Salvi

1 reference

Europe PubMed Central

26 July 2017

Débora Andréa Evangelista Façanha

7

object named as

Andrea Evangelista

1 reference

Europe PubMed Central

26 July 2017

Annalia Molinari

9

object named as

Annalia Molinari

1 reference

Europe PubMed Central

26 July 2017

10

object named as

Luigi Rigacci

1 reference

Europe PubMed Central

26 July 2017

11

object named as

Monica Tani

1 reference

Europe PubMed Central

26 July 2017

14

object named as

Alberto Fabbri

1 reference

Europe PubMed Central

26 July 2017

Renato Zambello

15

object named as

Renato Zambello

1 reference

Europe PubMed Central

26 July 2017

17

object named as

Manuel Gotti

1 reference

Europe PubMed Central

26 July 2017

author name string

Carlo Visco

1

1 reference

Europe PubMed Central

26 July 2017

Luca Nassi

3

1 reference

Europe PubMed Central

26 July 2017

Caterina Patti

4

1 reference

Europe PubMed Central

26 July 2017

Daniela Barbero

6

1 reference

Europe PubMed Central

26 July 2017

Alice Di Rocco

12

1 reference

Europe PubMed Central

26 July 2017

Silvia Finotto

16

1 reference

Europe PubMed Central

26 July 2017

Angelo M Carella

18

1 reference

Europe PubMed Central

26 July 2017

Marco Ruggeri

24

1 reference

Europe PubMed Central

26 July 2017

Maurizio Martelli

25

1 reference

Europe PubMed Central

26 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

2 December 2016

1 reference

Europe PubMed Central

26 July 2017

The Lancet. Haematology.

1 reference

Europe PubMed Central

26 July 2017

4

1 reference

Europe PubMed Central

26 July 2017

1

1 reference

Europe PubMed Central

26 July 2017

e15-e23

1 reference

Europe PubMed Central

26 July 2017

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of older patients with mantle-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymp

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Incorporating toxicity considerations into the design of two-stage phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Methods of joint evaluation of efficacy and toxicity in phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Databa

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2816%2930185-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2352-3026(16)30185-5

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33437445&oldid=2095826005"